Related Experiment Video
Updated: Jun 26, 2026
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
QSAR analysis and molecular modeling of ABCG2-specific inhibitors
E Nicolle1, A Boumendjel, S Macalou
1Département de Pharmacochimie Moléculaire, UMR 5063. ICMG-FR 2607-Université Joseph Fourier Grenoble I, 470 rue de la Chimie, 38240 St Martin d'Hères, France.
Abstract:
In addition to its critical role is controlling drug availability and protecting sensitive organs and stem cells through cellular detoxification, breast cancer resistance protein (BCRP/ABCG2) plays an important role in cancer cell resistance to chemotherapy, together with P-glycoprotein/ABCB1. A main approach to abolish multidrug resistance is to find out specific inhibitors of the drug-efflux activity, able to chemosensitize cancer cell proliferation. Many efforts have been primarily focused on ABCB1, discovered thirty years ago, whereas very few studies have concerned ABCG2, identified much more recently. This review describes the main types of inhibitors presently known for ABCG2, and how quantitative structure-activity relationship analysis among series of compounds may lead to build up molecular models and pharmacophores allowing to design lead inhibitors as future candidates for clinical trials. A special attention is drawn on flavonoids which constitute a structurally-diverse class of compounds, well suited to identify potent ABCG2-specific inhibitors.
Insights
Breast cancer resistance protein (BCRP/ABCG2) contributes to chemotherapy resistance. This review explores inhibitors, particularly flavonoids, to overcome BCRP/ABCG2-mediated multidrug resistance and improve cancer treatment efficacy.
Area of Science:
- Biochemistry
- Pharmacology
- Medicinal Chemistry
Background:
- Breast cancer resistance protein (BCRP/ABCG2) is a key transporter involved in multidrug resistance (MDR) in cancer, alongside P-glycoprotein (ABCB1).
- BCRP/ABCG2 mediates drug efflux, protecting cells and organs but also conferring resistance to chemotherapy agents.
- Targeting ABCG2 is crucial for developing strategies to chemosensitize cancer cells and overcome MDR.
Purpose of the Study:
- To review known inhibitors of breast cancer resistance protein (BCRP/ABCG2).
- To explore the application of quantitative structure-activity relationship (QSAR) analysis in designing novel BCRP/ABCG2 inhibitors.
- To highlight flavonoids as a promising class of compounds for developing BCRP/ABCG2-specific inhibitors.
Main Methods:
- Literature review of BCRP/ABCG2 inhibitors.
- Analysis of quantitative structure-activity relationships (QSAR) for inhibitor design.
- Focus on structural diversity and potency of flavonoid compounds against ABCG2.
Main Results:
- Various classes of BCRP/ABCG2 inhibitors have been identified.
- QSAR studies provide molecular models and pharmacophores for rational inhibitor design.
- Flavonoids show significant potential as potent and specific ABCG2 inhibitors due to their structural diversity.
Conclusions:
- Developing specific BCRP/ABCG2 inhibitors is essential for overcoming chemotherapy resistance.
- QSAR analysis is a valuable tool for designing effective lead compounds.
- Flavonoids represent a promising scaffold for future development of BCRP/ABCG2 inhibitors for clinical applications.
